Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
INTEGRILIN | Merck & Co | N-020718 DISCN | 1998-05-18 | 2 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
eptifibatide | ANDA | 2024-12-19 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
myocardial infarction | EFO_0000612 | D009203 | I21 |
coronary disease | — | D003327 | — |
unstable angina | EFO_1000985 | D000789 | I20.0 |
Code | Description |
---|---|
G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
J1327 | Injection, eptifibatide, 5 mg |
Drug common name | Eptifibatide |
INN | eptifibatide |
Description | Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
|
Classification | Protein |
Drug class | peptides: platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O |
PDB | — |
CAS-ID | 188627-80-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1174 |
ChEBI ID | 291902 |
PubChem CID | 123610 |
DrugBank | DB00063 |
UNII ID | NA8320J834 (ChemIDplus, GSRS) |